Global Immuno-oncology Diagnosis Market Growth (Status and Outlook) 2026-2032
The global Immuno-oncology Diagnosis market size is predicted to grow from US$ 8807 million in 2025 to US$ 20613 million in 2032; it is expected to grow at a CAGR of 13.1% from 2026 to 2032.
Immuno-oncology diagnostics refers to a comprehensive system of precise detection and evaluation technologies surrounding tumor immunotherapy. Its core lies in detecting key biomarkers in tumors and their immune microenvironment, combined with molecular diagnostics, immunohistochemistry, and next-generation sequencing to screen patients for suitability for immunotherapies such as Immune Checkpoint Inhibitors, predict efficacy, and dynamically monitor their progress. This enables integrated, personalized treatment decisions encompassing diagnosis, medication, and efficacy evaluation, making it a crucial entry point technology within the precision medicine
The growth logic of immuno-oncology diagnostics is highly dependent on the expansion of tumor immunotherapy. With the continuous expansion of the indications for immunotherapies such as PD-1/PD-L1 in multiple cancer types, and the emergence of new therapies such as CAR-T and bispecific antibodies, the demand for precise patient screening and companion diagnostics is rapidly increasing. At the same time, the industry is upgrading from single biomarker detection to multi-omics integrated analysis, and the combination of liquid biopsy and AI algorithms is driving the trend of 'non-invasive + dynamic' monitoring, significantly improving clinical value and frequency of use. At the regulatory level, the 'drug + diagnostic' collaborative approval model is being strengthened, forming a deep bond between leading diagnostic companies and pharmaceutical companies, further raising industry barriers. It is expected that this field will continue to maintain medium-to-high-speed growth in the next 5-10 years, becoming one of the most core infrastructures in the precision medicine and cancer treatment system.
LPI (LP Information)' newest research report, the ?Immuno-oncology Diagnosis Industry Forecast? looks at past sales and reviews total world Immuno-oncology Diagnosis sales in 2025, providing a comprehensive analysis by region and market sector of projected Immuno-oncology Diagnosis sales for 2026 through 2032. With Immuno-oncology Diagnosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immuno-oncology Diagnosis industry.
This Insight Report provides a comprehensive analysis of the global Immuno-oncology Diagnosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immuno-oncology Diagnosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Immuno-oncology Diagnosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immuno-oncology Diagnosis and breaks down the forecast by Technology Path, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immuno-oncology Diagnosis.
This report presents a comprehensive overview, market shares, and growth opportunities of Immuno-oncology Diagnosis market by product type, application, key players and key regions and countries.
Segmentation by Technology Path:
Immuno-oncology diagnostics refers to a comprehensive system of precise detection and evaluation technologies surrounding tumor immunotherapy. Its core lies in detecting key biomarkers in tumors and their immune microenvironment, combined with molecular diagnostics, immunohistochemistry, and next-generation sequencing to screen patients for suitability for immunotherapies such as Immune Checkpoint Inhibitors, predict efficacy, and dynamically monitor their progress. This enables integrated, personalized treatment decisions encompassing diagnosis, medication, and efficacy evaluation, making it a crucial entry point technology within the precision medicine
The growth logic of immuno-oncology diagnostics is highly dependent on the expansion of tumor immunotherapy. With the continuous expansion of the indications for immunotherapies such as PD-1/PD-L1 in multiple cancer types, and the emergence of new therapies such as CAR-T and bispecific antibodies, the demand for precise patient screening and companion diagnostics is rapidly increasing. At the same time, the industry is upgrading from single biomarker detection to multi-omics integrated analysis, and the combination of liquid biopsy and AI algorithms is driving the trend of 'non-invasive + dynamic' monitoring, significantly improving clinical value and frequency of use. At the regulatory level, the 'drug + diagnostic' collaborative approval model is being strengthened, forming a deep bond between leading diagnostic companies and pharmaceutical companies, further raising industry barriers. It is expected that this field will continue to maintain medium-to-high-speed growth in the next 5-10 years, becoming one of the most core infrastructures in the precision medicine and cancer treatment system.
LPI (LP Information)' newest research report, the ?Immuno-oncology Diagnosis Industry Forecast? looks at past sales and reviews total world Immuno-oncology Diagnosis sales in 2025, providing a comprehensive analysis by region and market sector of projected Immuno-oncology Diagnosis sales for 2026 through 2032. With Immuno-oncology Diagnosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immuno-oncology Diagnosis industry.
This Insight Report provides a comprehensive analysis of the global Immuno-oncology Diagnosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immuno-oncology Diagnosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Immuno-oncology Diagnosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immuno-oncology Diagnosis and breaks down the forecast by Technology Path, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immuno-oncology Diagnosis.
This report presents a comprehensive overview, market shares, and growth opportunities of Immuno-oncology Diagnosis market by product type, application, key players and key regions and countries.
Segmentation by Technology Path:
- Immunohistochemistry
- Molecular Diagnostics
- High-Throughput Sequencing
- Liquid Biopsy
- Multi-omics Integrated Analysis
- Immune Checkpoint Biomarkers
- Tumor Mutation Burden
- Microsatellite Instability
- Tumor-Infiltrating Lymphocytes
- Immune-Related Gene Expression Profiling
- Immunodiagnostics for Solid Tumors
- Immunodiagnostics for Hematologic Malignancies
- Tumor Microenvironment (TME) Analysis
- Research
- Diagnostics
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Guardant Health (USA)
- Foundation Medicine (USA)
- Illumina (USA)
- Thermo Fisher Scientific (USA)
- LabCorp (USA)
- NeoGenomics (USA)
- Myriad Genetics (USA)
- Caris Life Sciences (USA)
- Roche (Switzerland)
- BioM?rieux (France)
- QIAGEN (Netherlands)
- Burning Rock Biotech (China)
- Novogene (China)
- BGI Genomics (China)
- Sysmex (Japan)
- Fujirebio (Japan)
- IMBDx (South Korea)
- Seegene (South Korea)
- GeneMatrix (South Korea)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immuno-oncology Diagnosis Market Size (2021-2032)
2.1.2 Immuno-oncology Diagnosis Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Immuno-oncology Diagnosis by Country/Region (2021, 2025 & 2032)
2.2 Immuno-oncology Diagnosis Segment by Technology Path
2.2.1 Immunohistochemistry
2.2.2 Molecular Diagnostics
2.2.3 High-Throughput Sequencing
2.2.4 Liquid Biopsy
2.2.5 Multi-omics Integrated Analysis
2.2.6 Immuno-oncology Diagnosis Market Size by Technology Path
2.2.6.1 Immuno-oncology Diagnosis Market Size CAGR by Technology Path (2021 VS 2025 VS 2032)
2.2.6.2 Global Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
2.3 Immuno-oncology Diagnosis Segment by Detection Biomarkers
2.3.1 Immune Checkpoint Biomarkers
2.3.2 Tumor Mutation Burden
2.3.3 Microsatellite Instability
2.3.4 Tumor-Infiltrating Lymphocytes
2.3.5 Immune-Related Gene Expression Profiling
2.3.6 Immuno-oncology Diagnosis Market Size by Detection Biomarkers
2.3.6.1 Immuno-oncology Diagnosis Market Size CAGR by Detection Biomarkers (2021 VS 2025 VS 2032)
2.3.6.2 Global Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2021-2026)
2.4 Immuno-oncology Diagnosis Segment by Use Scenarios
2.4.1 Immunodiagnostics for Solid Tumors
2.4.2 Immunodiagnostics for Hematologic Malignancies
2.4.3 Tumor Microenvironment (TME) Analysis
2.4.4 Immuno-oncology Diagnosis Market Size by Use Scenarios
2.4.4.1 Immuno-oncology Diagnosis Market Size CAGR by Use Scenarios (2021 VS 2025 VS 2032)
2.4.4.2 Global Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2021-2026)
2.5 Immuno-oncology Diagnosis Segment by Application
2.5.1 Research
2.5.2 Diagnostics
2.5.3 Immuno-oncology Diagnosis Market Size by Application
2.5.3.1 Immuno-oncology Diagnosis Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.3.2 Global Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
3 IMMUNO-ONCOLOGY DIAGNOSIS MARKET SIZE BY PLAYER
3.1 Immuno-oncology Diagnosis Market Size Market Share by Player
3.1.1 Global Immuno-oncology Diagnosis Revenue by Player (2021-2026)
3.1.2 Global Immuno-oncology Diagnosis Revenue Market Share by Player (2021-2026)
3.2 Global Immuno-oncology Diagnosis Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNO-ONCOLOGY DIAGNOSIS BY REGION
4.1 Immuno-oncology Diagnosis Market Size by Region (2021-2026)
4.2 Global Immuno-oncology Diagnosis Annual Revenue by Country/Region (2021-2026)
4.3 Americas Immuno-oncology Diagnosis Market Size Growth (2021-2026)
4.4 APAC Immuno-oncology Diagnosis Market Size Growth (2021-2026)
4.5 Europe Immuno-oncology Diagnosis Market Size Growth (2021-2026)
4.6 Middle East & Africa Immuno-oncology Diagnosis Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Immuno-oncology Diagnosis Market Size by Country (2021-2026)
5.2 Americas Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
5.3 Americas Immuno-oncology Diagnosis Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immuno-oncology Diagnosis Market Size by Region (2021-2026)
6.2 APAC Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
6.3 APAC Immuno-oncology Diagnosis Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immuno-oncology Diagnosis Market Size by Country (2021-2026)
7.2 Europe Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
7.3 Europe Immuno-oncology Diagnosis Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immuno-oncology Diagnosis by Region (2021-2026)
8.2 Middle East & Africa Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
8.3 Middle East & Africa Immuno-oncology Diagnosis Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNO-ONCOLOGY DIAGNOSIS MARKET FORECAST
10.1 Global Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.1.1 Global Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.1.2 Americas Immuno-oncology Diagnosis Forecast
10.1.3 APAC Immuno-oncology Diagnosis Forecast
10.1.4 Europe Immuno-oncology Diagnosis Forecast
10.1.5 Middle East & Africa Immuno-oncology Diagnosis Forecast
10.2 Americas Immuno-oncology Diagnosis Forecast by Country (2027-2032)
10.2.1 United States Market Immuno-oncology Diagnosis Forecast
10.2.2 Canada Market Immuno-oncology Diagnosis Forecast
10.2.3 Mexico Market Immuno-oncology Diagnosis Forecast
10.2.4 Brazil Market Immuno-oncology Diagnosis Forecast
10.3 APAC Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.3.1 China Immuno-oncology Diagnosis Market Forecast
10.3.2 Japan Market Immuno-oncology Diagnosis Forecast
10.3.3 Korea Market Immuno-oncology Diagnosis Forecast
10.3.4 Southeast Asia Market Immuno-oncology Diagnosis Forecast
10.3.5 India Market Immuno-oncology Diagnosis Forecast
10.3.6 Australia Market Immuno-oncology Diagnosis Forecast
10.4 Europe Immuno-oncology Diagnosis Forecast by Country (2027-2032)
10.4.1 Germany Market Immuno-oncology Diagnosis Forecast
10.4.2 France Market Immuno-oncology Diagnosis Forecast
10.4.3 UK Market Immuno-oncology Diagnosis Forecast
10.4.4 Italy Market Immuno-oncology Diagnosis Forecast
10.4.5 Russia Market Immuno-oncology Diagnosis Forecast
10.5 Middle East & Africa Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.5.1 Egypt Market Immuno-oncology Diagnosis Forecast
10.5.2 South Africa Market Immuno-oncology Diagnosis Forecast
10.5.3 Israel Market Immuno-oncology Diagnosis Forecast
10.5.4 Turkey Market Immuno-oncology Diagnosis Forecast
10.6 Global Immuno-oncology Diagnosis Forecast by Technology Path (2027-2032)
10.7 Global Immuno-oncology Diagnosis Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Immuno-oncology Diagnosis Forecast
11 KEY PLAYERS ANALYSIS
11.1 Guardant Health (USA)
11.1.1 Guardant Health (USA) Company Information
11.1.2 Guardant Health (USA) Immuno-oncology Diagnosis Product Offered
11.1.3 Guardant Health (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Guardant Health (USA) Main Business Overview
11.1.5 Guardant Health (USA) Latest Developments
11.2 Foundation Medicine (USA)
11.2.1 Foundation Medicine (USA) Company Information
11.2.2 Foundation Medicine (USA) Immuno-oncology Diagnosis Product Offered
11.2.3 Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Foundation Medicine (USA) Main Business Overview
11.2.5 Foundation Medicine (USA) Latest Developments
11.3 Illumina (USA)
11.3.1 Illumina (USA) Company Information
11.3.2 Illumina (USA) Immuno-oncology Diagnosis Product Offered
11.3.3 Illumina (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Illumina (USA) Main Business Overview
11.3.5 Illumina (USA) Latest Developments
11.4 Thermo Fisher Scientific (USA)
11.4.1 Thermo Fisher Scientific (USA) Company Information
11.4.2 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product Offered
11.4.3 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Thermo Fisher Scientific (USA) Main Business Overview
11.4.5 Thermo Fisher Scientific (USA) Latest Developments
11.5 LabCorp (USA)
11.5.1 LabCorp (USA) Company Information
11.5.2 LabCorp (USA) Immuno-oncology Diagnosis Product Offered
11.5.3 LabCorp (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 LabCorp (USA) Main Business Overview
11.5.5 LabCorp (USA) Latest Developments
11.6 NeoGenomics (USA)
11.6.1 NeoGenomics (USA) Company Information
11.6.2 NeoGenomics (USA) Immuno-oncology Diagnosis Product Offered
11.6.3 NeoGenomics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 NeoGenomics (USA) Main Business Overview
11.6.5 NeoGenomics (USA) Latest Developments
11.7 Myriad Genetics (USA)
11.7.1 Myriad Genetics (USA) Company Information
11.7.2 Myriad Genetics (USA) Immuno-oncology Diagnosis Product Offered
11.7.3 Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Myriad Genetics (USA) Main Business Overview
11.7.5 Myriad Genetics (USA) Latest Developments
11.8 Caris Life Sciences (USA)
11.8.1 Caris Life Sciences (USA) Company Information
11.8.2 Caris Life Sciences (USA) Immuno-oncology Diagnosis Product Offered
11.8.3 Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Caris Life Sciences (USA) Main Business Overview
11.8.5 Caris Life Sciences (USA) Latest Developments
11.9 Roche (Switzerland)
11.9.1 Roche (Switzerland) Company Information
11.9.2 Roche (Switzerland) Immuno-oncology Diagnosis Product Offered
11.9.3 Roche (Switzerland) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Roche (Switzerland) Main Business Overview
11.9.5 Roche (Switzerland) Latest Developments
11.10 BioM?rieux (France)
11.10.1 BioM?rieux (France) Company Information
11.10.2 BioM?rieux (France) Immuno-oncology Diagnosis Product Offered
11.10.3 BioM?rieux (France) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BioM?rieux (France) Main Business Overview
11.10.5 BioM?rieux (France) Latest Developments
11.11 QIAGEN (Netherlands)
11.11.1 QIAGEN (Netherlands) Company Information
11.11.2 QIAGEN (Netherlands) Immuno-oncology Diagnosis Product Offered
11.11.3 QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 QIAGEN (Netherlands) Main Business Overview
11.11.5 QIAGEN (Netherlands) Latest Developments
11.12 Burning Rock Biotech (China)
11.12.1 Burning Rock Biotech (China) Company Information
11.12.2 Burning Rock Biotech (China) Immuno-oncology Diagnosis Product Offered
11.12.3 Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Burning Rock Biotech (China) Main Business Overview
11.12.5 Burning Rock Biotech (China) Latest Developments
11.13 Novogene (China)
11.13.1 Novogene (China) Company Information
11.13.2 Novogene (China) Immuno-oncology Diagnosis Product Offered
11.13.3 Novogene (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Novogene (China) Main Business Overview
11.13.5 Novogene (China) Latest Developments
11.14 BGI Genomics (China)
11.14.1 BGI Genomics (China) Company Information
11.14.2 BGI Genomics (China) Immuno-oncology Diagnosis Product Offered
11.14.3 BGI Genomics (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 BGI Genomics (China) Main Business Overview
11.14.5 BGI Genomics (China) Latest Developments
11.15 Sysmex (Japan)
11.15.1 Sysmex (Japan) Company Information
11.15.2 Sysmex (Japan) Immuno-oncology Diagnosis Product Offered
11.15.3 Sysmex (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Sysmex (Japan) Main Business Overview
11.15.5 Sysmex (Japan) Latest Developments
11.16 Fujirebio (Japan)
11.16.1 Fujirebio (Japan) Company Information
11.16.2 Fujirebio (Japan) Immuno-oncology Diagnosis Product Offered
11.16.3 Fujirebio (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Fujirebio (Japan) Main Business Overview
11.16.5 Fujirebio (Japan) Latest Developments
11.17 IMBDx (South Korea)
11.17.1 IMBDx (South Korea) Company Information
11.17.2 IMBDx (South Korea) Immuno-oncology Diagnosis Product Offered
11.17.3 IMBDx (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 IMBDx (South Korea) Main Business Overview
11.17.5 IMBDx (South Korea) Latest Developments
11.18 Seegene (South Korea)
11.18.1 Seegene (South Korea) Company Information
11.18.2 Seegene (South Korea) Immuno-oncology Diagnosis Product Offered
11.18.3 Seegene (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Seegene (South Korea) Main Business Overview
11.18.5 Seegene (South Korea) Latest Developments
11.19 GeneMatrix (South Korea)
11.19.1 GeneMatrix (South Korea) Company Information
11.19.2 GeneMatrix (South Korea) Immuno-oncology Diagnosis Product Offered
11.19.3 GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 GeneMatrix (South Korea) Main Business Overview
11.19.5 GeneMatrix (South Korea) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immuno-oncology Diagnosis Market Size (2021-2032)
2.1.2 Immuno-oncology Diagnosis Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Immuno-oncology Diagnosis by Country/Region (2021, 2025 & 2032)
2.2 Immuno-oncology Diagnosis Segment by Technology Path
2.2.1 Immunohistochemistry
2.2.2 Molecular Diagnostics
2.2.3 High-Throughput Sequencing
2.2.4 Liquid Biopsy
2.2.5 Multi-omics Integrated Analysis
2.2.6 Immuno-oncology Diagnosis Market Size by Technology Path
2.2.6.1 Immuno-oncology Diagnosis Market Size CAGR by Technology Path (2021 VS 2025 VS 2032)
2.2.6.2 Global Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
2.3 Immuno-oncology Diagnosis Segment by Detection Biomarkers
2.3.1 Immune Checkpoint Biomarkers
2.3.2 Tumor Mutation Burden
2.3.3 Microsatellite Instability
2.3.4 Tumor-Infiltrating Lymphocytes
2.3.5 Immune-Related Gene Expression Profiling
2.3.6 Immuno-oncology Diagnosis Market Size by Detection Biomarkers
2.3.6.1 Immuno-oncology Diagnosis Market Size CAGR by Detection Biomarkers (2021 VS 2025 VS 2032)
2.3.6.2 Global Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2021-2026)
2.4 Immuno-oncology Diagnosis Segment by Use Scenarios
2.4.1 Immunodiagnostics for Solid Tumors
2.4.2 Immunodiagnostics for Hematologic Malignancies
2.4.3 Tumor Microenvironment (TME) Analysis
2.4.4 Immuno-oncology Diagnosis Market Size by Use Scenarios
2.4.4.1 Immuno-oncology Diagnosis Market Size CAGR by Use Scenarios (2021 VS 2025 VS 2032)
2.4.4.2 Global Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2021-2026)
2.5 Immuno-oncology Diagnosis Segment by Application
2.5.1 Research
2.5.2 Diagnostics
2.5.3 Immuno-oncology Diagnosis Market Size by Application
2.5.3.1 Immuno-oncology Diagnosis Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.3.2 Global Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
3 IMMUNO-ONCOLOGY DIAGNOSIS MARKET SIZE BY PLAYER
3.1 Immuno-oncology Diagnosis Market Size Market Share by Player
3.1.1 Global Immuno-oncology Diagnosis Revenue by Player (2021-2026)
3.1.2 Global Immuno-oncology Diagnosis Revenue Market Share by Player (2021-2026)
3.2 Global Immuno-oncology Diagnosis Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNO-ONCOLOGY DIAGNOSIS BY REGION
4.1 Immuno-oncology Diagnosis Market Size by Region (2021-2026)
4.2 Global Immuno-oncology Diagnosis Annual Revenue by Country/Region (2021-2026)
4.3 Americas Immuno-oncology Diagnosis Market Size Growth (2021-2026)
4.4 APAC Immuno-oncology Diagnosis Market Size Growth (2021-2026)
4.5 Europe Immuno-oncology Diagnosis Market Size Growth (2021-2026)
4.6 Middle East & Africa Immuno-oncology Diagnosis Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Immuno-oncology Diagnosis Market Size by Country (2021-2026)
5.2 Americas Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
5.3 Americas Immuno-oncology Diagnosis Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immuno-oncology Diagnosis Market Size by Region (2021-2026)
6.2 APAC Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
6.3 APAC Immuno-oncology Diagnosis Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immuno-oncology Diagnosis Market Size by Country (2021-2026)
7.2 Europe Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
7.3 Europe Immuno-oncology Diagnosis Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immuno-oncology Diagnosis by Region (2021-2026)
8.2 Middle East & Africa Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026)
8.3 Middle East & Africa Immuno-oncology Diagnosis Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNO-ONCOLOGY DIAGNOSIS MARKET FORECAST
10.1 Global Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.1.1 Global Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.1.2 Americas Immuno-oncology Diagnosis Forecast
10.1.3 APAC Immuno-oncology Diagnosis Forecast
10.1.4 Europe Immuno-oncology Diagnosis Forecast
10.1.5 Middle East & Africa Immuno-oncology Diagnosis Forecast
10.2 Americas Immuno-oncology Diagnosis Forecast by Country (2027-2032)
10.2.1 United States Market Immuno-oncology Diagnosis Forecast
10.2.2 Canada Market Immuno-oncology Diagnosis Forecast
10.2.3 Mexico Market Immuno-oncology Diagnosis Forecast
10.2.4 Brazil Market Immuno-oncology Diagnosis Forecast
10.3 APAC Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.3.1 China Immuno-oncology Diagnosis Market Forecast
10.3.2 Japan Market Immuno-oncology Diagnosis Forecast
10.3.3 Korea Market Immuno-oncology Diagnosis Forecast
10.3.4 Southeast Asia Market Immuno-oncology Diagnosis Forecast
10.3.5 India Market Immuno-oncology Diagnosis Forecast
10.3.6 Australia Market Immuno-oncology Diagnosis Forecast
10.4 Europe Immuno-oncology Diagnosis Forecast by Country (2027-2032)
10.4.1 Germany Market Immuno-oncology Diagnosis Forecast
10.4.2 France Market Immuno-oncology Diagnosis Forecast
10.4.3 UK Market Immuno-oncology Diagnosis Forecast
10.4.4 Italy Market Immuno-oncology Diagnosis Forecast
10.4.5 Russia Market Immuno-oncology Diagnosis Forecast
10.5 Middle East & Africa Immuno-oncology Diagnosis Forecast by Region (2027-2032)
10.5.1 Egypt Market Immuno-oncology Diagnosis Forecast
10.5.2 South Africa Market Immuno-oncology Diagnosis Forecast
10.5.3 Israel Market Immuno-oncology Diagnosis Forecast
10.5.4 Turkey Market Immuno-oncology Diagnosis Forecast
10.6 Global Immuno-oncology Diagnosis Forecast by Technology Path (2027-2032)
10.7 Global Immuno-oncology Diagnosis Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Immuno-oncology Diagnosis Forecast
11 KEY PLAYERS ANALYSIS
11.1 Guardant Health (USA)
11.1.1 Guardant Health (USA) Company Information
11.1.2 Guardant Health (USA) Immuno-oncology Diagnosis Product Offered
11.1.3 Guardant Health (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Guardant Health (USA) Main Business Overview
11.1.5 Guardant Health (USA) Latest Developments
11.2 Foundation Medicine (USA)
11.2.1 Foundation Medicine (USA) Company Information
11.2.2 Foundation Medicine (USA) Immuno-oncology Diagnosis Product Offered
11.2.3 Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Foundation Medicine (USA) Main Business Overview
11.2.5 Foundation Medicine (USA) Latest Developments
11.3 Illumina (USA)
11.3.1 Illumina (USA) Company Information
11.3.2 Illumina (USA) Immuno-oncology Diagnosis Product Offered
11.3.3 Illumina (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Illumina (USA) Main Business Overview
11.3.5 Illumina (USA) Latest Developments
11.4 Thermo Fisher Scientific (USA)
11.4.1 Thermo Fisher Scientific (USA) Company Information
11.4.2 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product Offered
11.4.3 Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Thermo Fisher Scientific (USA) Main Business Overview
11.4.5 Thermo Fisher Scientific (USA) Latest Developments
11.5 LabCorp (USA)
11.5.1 LabCorp (USA) Company Information
11.5.2 LabCorp (USA) Immuno-oncology Diagnosis Product Offered
11.5.3 LabCorp (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 LabCorp (USA) Main Business Overview
11.5.5 LabCorp (USA) Latest Developments
11.6 NeoGenomics (USA)
11.6.1 NeoGenomics (USA) Company Information
11.6.2 NeoGenomics (USA) Immuno-oncology Diagnosis Product Offered
11.6.3 NeoGenomics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 NeoGenomics (USA) Main Business Overview
11.6.5 NeoGenomics (USA) Latest Developments
11.7 Myriad Genetics (USA)
11.7.1 Myriad Genetics (USA) Company Information
11.7.2 Myriad Genetics (USA) Immuno-oncology Diagnosis Product Offered
11.7.3 Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Myriad Genetics (USA) Main Business Overview
11.7.5 Myriad Genetics (USA) Latest Developments
11.8 Caris Life Sciences (USA)
11.8.1 Caris Life Sciences (USA) Company Information
11.8.2 Caris Life Sciences (USA) Immuno-oncology Diagnosis Product Offered
11.8.3 Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Caris Life Sciences (USA) Main Business Overview
11.8.5 Caris Life Sciences (USA) Latest Developments
11.9 Roche (Switzerland)
11.9.1 Roche (Switzerland) Company Information
11.9.2 Roche (Switzerland) Immuno-oncology Diagnosis Product Offered
11.9.3 Roche (Switzerland) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Roche (Switzerland) Main Business Overview
11.9.5 Roche (Switzerland) Latest Developments
11.10 BioM?rieux (France)
11.10.1 BioM?rieux (France) Company Information
11.10.2 BioM?rieux (France) Immuno-oncology Diagnosis Product Offered
11.10.3 BioM?rieux (France) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BioM?rieux (France) Main Business Overview
11.10.5 BioM?rieux (France) Latest Developments
11.11 QIAGEN (Netherlands)
11.11.1 QIAGEN (Netherlands) Company Information
11.11.2 QIAGEN (Netherlands) Immuno-oncology Diagnosis Product Offered
11.11.3 QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 QIAGEN (Netherlands) Main Business Overview
11.11.5 QIAGEN (Netherlands) Latest Developments
11.12 Burning Rock Biotech (China)
11.12.1 Burning Rock Biotech (China) Company Information
11.12.2 Burning Rock Biotech (China) Immuno-oncology Diagnosis Product Offered
11.12.3 Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Burning Rock Biotech (China) Main Business Overview
11.12.5 Burning Rock Biotech (China) Latest Developments
11.13 Novogene (China)
11.13.1 Novogene (China) Company Information
11.13.2 Novogene (China) Immuno-oncology Diagnosis Product Offered
11.13.3 Novogene (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Novogene (China) Main Business Overview
11.13.5 Novogene (China) Latest Developments
11.14 BGI Genomics (China)
11.14.1 BGI Genomics (China) Company Information
11.14.2 BGI Genomics (China) Immuno-oncology Diagnosis Product Offered
11.14.3 BGI Genomics (China) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 BGI Genomics (China) Main Business Overview
11.14.5 BGI Genomics (China) Latest Developments
11.15 Sysmex (Japan)
11.15.1 Sysmex (Japan) Company Information
11.15.2 Sysmex (Japan) Immuno-oncology Diagnosis Product Offered
11.15.3 Sysmex (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Sysmex (Japan) Main Business Overview
11.15.5 Sysmex (Japan) Latest Developments
11.16 Fujirebio (Japan)
11.16.1 Fujirebio (Japan) Company Information
11.16.2 Fujirebio (Japan) Immuno-oncology Diagnosis Product Offered
11.16.3 Fujirebio (Japan) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Fujirebio (Japan) Main Business Overview
11.16.5 Fujirebio (Japan) Latest Developments
11.17 IMBDx (South Korea)
11.17.1 IMBDx (South Korea) Company Information
11.17.2 IMBDx (South Korea) Immuno-oncology Diagnosis Product Offered
11.17.3 IMBDx (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 IMBDx (South Korea) Main Business Overview
11.17.5 IMBDx (South Korea) Latest Developments
11.18 Seegene (South Korea)
11.18.1 Seegene (South Korea) Company Information
11.18.2 Seegene (South Korea) Immuno-oncology Diagnosis Product Offered
11.18.3 Seegene (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Seegene (South Korea) Main Business Overview
11.18.5 Seegene (South Korea) Latest Developments
11.19 GeneMatrix (South Korea)
11.19.1 GeneMatrix (South Korea) Company Information
11.19.2 GeneMatrix (South Korea) Immuno-oncology Diagnosis Product Offered
11.19.3 GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 GeneMatrix (South Korea) Main Business Overview
11.19.5 GeneMatrix (South Korea) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Immuno-oncology Diagnosis Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Immuno-oncology Diagnosis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Immunohistochemistry
Table 4. Major Players of Molecular Diagnostics
Table 5. Major Players of High-Throughput Sequencing
Table 6. Major Players of Liquid Biopsy
Table 7. Major Players of Multi-omics Integrated Analysis
Table 8. Immuno-oncology Diagnosis Market Size CAGR by Technology Path (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 10. Global Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Table 11. Major Players of Immune Checkpoint Biomarkers
Table 12. Major Players of Tumor Mutation Burden
Table 13. Major Players of Microsatellite Instability
Table 14. Major Players of Tumor-Infiltrating Lymphocytes
Table 15. Major Players of Immune-Related Gene Expression Profiling
Table 16. Immuno-oncology Diagnosis Market Size CAGR by Detection Biomarkers (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2021-2026) & ($ millions)
Table 18. Global Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2021-2026)
Table 19. Major Players of Immunodiagnostics for Solid Tumors
Table 20. Major Players of Immunodiagnostics for Hematologic Malignancies
Table 21. Major Players of Tumor Microenvironment (TME) Analysis
Table 22. Immuno-oncology Diagnosis Market Size CAGR by Use Scenarios (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Immuno-oncology Diagnosis Market Size by Use Scenarios (2021-2026) & ($ millions)
Table 24. Global Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2021-2026)
Table 25. Immuno-oncology Diagnosis Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 26. Global Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 27. Global Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Table 28. Global Immuno-oncology Diagnosis Revenue by Player (2021-2026) & ($ millions)
Table 29. Global Immuno-oncology Diagnosis Revenue Market Share by Player (2021-2026)
Table 30. Immuno-oncology Diagnosis Key Players Head office and Products Offered
Table 31. Immuno-oncology Diagnosis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 32. New Products and Potential Entrants
Table 33. Mergers & Acquisitions, Expansion
Table 34. Global Immuno-oncology Diagnosis Market Size by Region (2021-2026) & ($ millions)
Table 35. Global Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Table 36. Global Immuno-oncology Diagnosis Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global Immuno-oncology Diagnosis Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas Immuno-oncology Diagnosis Market Size by Country (2021-2026) & ($ millions)
Table 39. Americas Immuno-oncology Diagnosis Market Size Market Share by Country (2021-2026)
Table 40. Americas Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 41. Americas Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Table 42. Americas Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 43. Americas Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Table 44. APAC Immuno-oncology Diagnosis Market Size by Region (2021-2026) & ($ millions)
Table 45. APAC Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Table 46. APAC Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 47. APAC Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 48. Europe Immuno-oncology Diagnosis Market Size by Country (2021-2026) & ($ millions)
Table 49. Europe Immuno-oncology Diagnosis Market Size Market Share by Country (2021-2026)
Table 50. Europe Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 51. Europe Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 52. Middle East & Africa Immuno-oncology Diagnosis Market Size by Region (2021-2026) & ($ millions)
Table 53. Middle East & Africa Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 54. Middle East & Africa Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 55. Key Market Drivers & Growth Opportunities of Immuno-oncology Diagnosis
Table 56. Key Market Challenges & Risks of Immuno-oncology Diagnosis
Table 57. Key Industry Trends of Immuno-oncology Diagnosis
Table 58. Global Immuno-oncology Diagnosis Market Size Forecast by Region (2027-2032) & ($ millions)
Table 59. Global Immuno-oncology Diagnosis Market Size Market Share Forecast by Region (2027-2032)
Table 60. Global Immuno-oncology Diagnosis Market Size Forecast by Technology Path (2027-2032) & ($ millions)
Table 61. Global Immuno-oncology Diagnosis Market Size Forecast by Application (2027-2032) & ($ millions)
Table 62. Guardant Health (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 63. Guardant Health (USA) Immuno-oncology Diagnosis Product Offered
Table 64. Guardant Health (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Guardant Health (USA) Main Business
Table 66. Guardant Health (USA) Latest Developments
Table 67. Foundation Medicine (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 68. Foundation Medicine (USA) Immuno-oncology Diagnosis Product Offered
Table 69. Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Foundation Medicine (USA) Main Business
Table 71. Foundation Medicine (USA) Latest Developments
Table 72. Illumina (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 73. Illumina (USA) Immuno-oncology Diagnosis Product Offered
Table 74. Illumina (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Illumina (USA) Main Business
Table 76. Illumina (USA) Latest Developments
Table 77. Thermo Fisher Scientific (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 78. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product Offered
Table 79. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Thermo Fisher Scientific (USA) Main Business
Table 81. Thermo Fisher Scientific (USA) Latest Developments
Table 82. LabCorp (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 83. LabCorp (USA) Immuno-oncology Diagnosis Product Offered
Table 84. LabCorp (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. LabCorp (USA) Main Business
Table 86. LabCorp (USA) Latest Developments
Table 87. NeoGenomics (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 88. NeoGenomics (USA) Immuno-oncology Diagnosis Product Offered
Table 89. NeoGenomics (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. NeoGenomics (USA) Main Business
Table 91. NeoGenomics (USA) Latest Developments
Table 92. Myriad Genetics (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 93. Myriad Genetics (USA) Immuno-oncology Diagnosis Product Offered
Table 94. Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Myriad Genetics (USA) Main Business
Table 96. Myriad Genetics (USA) Latest Developments
Table 97. Caris Life Sciences (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 98. Caris Life Sciences (USA) Immuno-oncology Diagnosis Product Offered
Table 99. Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Caris Life Sciences (USA) Main Business
Table 101. Caris Life Sciences (USA) Latest Developments
Table 102. Roche (Switzerland) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 103. Roche (Switzerland) Immuno-oncology Diagnosis Product Offered
Table 104. Roche (Switzerland) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Roche (Switzerland) Main Business
Table 106. Roche (Switzerland) Latest Developments
Table 107. BioM?rieux (France) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 108. BioM?rieux (France) Immuno-oncology Diagnosis Product Offered
Table 109. BioM?rieux (France) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. BioM?rieux (France) Main Business
Table 111. BioM?rieux (France) Latest Developments
Table 112. QIAGEN (Netherlands) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 113. QIAGEN (Netherlands) Immuno-oncology Diagnosis Product Offered
Table 114. QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. QIAGEN (Netherlands) Main Business
Table 116. QIAGEN (Netherlands) Latest Developments
Table 117. Burning Rock Biotech (China) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 118. Burning Rock Biotech (China) Immuno-oncology Diagnosis Product Offered
Table 119. Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. Burning Rock Biotech (China) Main Business
Table 121. Burning Rock Biotech (China) Latest Developments
Table 122. Novogene (China) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 123. Novogene (China) Immuno-oncology Diagnosis Product Offered
Table 124. Novogene (China) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Novogene (China) Main Business
Table 126. Novogene (China) Latest Developments
Table 127. BGI Genomics (China) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 128. BGI Genomics (China) Immuno-oncology Diagnosis Product Offered
Table 129. BGI Genomics (China) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. BGI Genomics (China) Main Business
Table 131. BGI Genomics (China) Latest Developments
Table 132. Sysmex (Japan) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 133. Sysmex (Japan) Immuno-oncology Diagnosis Product Offered
Table 134. Sysmex (Japan) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Sysmex (Japan) Main Business
Table 136. Sysmex (Japan) Latest Developments
Table 137. Fujirebio (Japan) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 138. Fujirebio (Japan) Immuno-oncology Diagnosis Product Offered
Table 139. Fujirebio (Japan) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Fujirebio (Japan) Main Business
Table 141. Fujirebio (Japan) Latest Developments
Table 142. IMBDx (South Korea) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 143. IMBDx (South Korea) Immuno-oncology Diagnosis Product Offered
Table 144. IMBDx (South Korea) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 145. IMBDx (South Korea) Main Business
Table 146. IMBDx (South Korea) Latest Developments
Table 147. Seegene (South Korea) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 148. Seegene (South Korea) Immuno-oncology Diagnosis Product Offered
Table 149. Seegene (South Korea) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 150. Seegene (South Korea) Main Business
Table 151. Seegene (South Korea) Latest Developments
Table 152. GeneMatrix (South Korea) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 153. GeneMatrix (South Korea) Immuno-oncology Diagnosis Product Offered
Table 154. GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 155. GeneMatrix (South Korea) Main Business
Table 156. GeneMatrix (South Korea) Latest Developments
Table 1. Immuno-oncology Diagnosis Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Immuno-oncology Diagnosis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Immunohistochemistry
Table 4. Major Players of Molecular Diagnostics
Table 5. Major Players of High-Throughput Sequencing
Table 6. Major Players of Liquid Biopsy
Table 7. Major Players of Multi-omics Integrated Analysis
Table 8. Immuno-oncology Diagnosis Market Size CAGR by Technology Path (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 10. Global Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Table 11. Major Players of Immune Checkpoint Biomarkers
Table 12. Major Players of Tumor Mutation Burden
Table 13. Major Players of Microsatellite Instability
Table 14. Major Players of Tumor-Infiltrating Lymphocytes
Table 15. Major Players of Immune-Related Gene Expression Profiling
Table 16. Immuno-oncology Diagnosis Market Size CAGR by Detection Biomarkers (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global Immuno-oncology Diagnosis Market Size by Detection Biomarkers (2021-2026) & ($ millions)
Table 18. Global Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers (2021-2026)
Table 19. Major Players of Immunodiagnostics for Solid Tumors
Table 20. Major Players of Immunodiagnostics for Hematologic Malignancies
Table 21. Major Players of Tumor Microenvironment (TME) Analysis
Table 22. Immuno-oncology Diagnosis Market Size CAGR by Use Scenarios (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Immuno-oncology Diagnosis Market Size by Use Scenarios (2021-2026) & ($ millions)
Table 24. Global Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios (2021-2026)
Table 25. Immuno-oncology Diagnosis Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 26. Global Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 27. Global Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Table 28. Global Immuno-oncology Diagnosis Revenue by Player (2021-2026) & ($ millions)
Table 29. Global Immuno-oncology Diagnosis Revenue Market Share by Player (2021-2026)
Table 30. Immuno-oncology Diagnosis Key Players Head office and Products Offered
Table 31. Immuno-oncology Diagnosis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 32. New Products and Potential Entrants
Table 33. Mergers & Acquisitions, Expansion
Table 34. Global Immuno-oncology Diagnosis Market Size by Region (2021-2026) & ($ millions)
Table 35. Global Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Table 36. Global Immuno-oncology Diagnosis Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global Immuno-oncology Diagnosis Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas Immuno-oncology Diagnosis Market Size by Country (2021-2026) & ($ millions)
Table 39. Americas Immuno-oncology Diagnosis Market Size Market Share by Country (2021-2026)
Table 40. Americas Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 41. Americas Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Table 42. Americas Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 43. Americas Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Table 44. APAC Immuno-oncology Diagnosis Market Size by Region (2021-2026) & ($ millions)
Table 45. APAC Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Table 46. APAC Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 47. APAC Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 48. Europe Immuno-oncology Diagnosis Market Size by Country (2021-2026) & ($ millions)
Table 49. Europe Immuno-oncology Diagnosis Market Size Market Share by Country (2021-2026)
Table 50. Europe Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 51. Europe Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 52. Middle East & Africa Immuno-oncology Diagnosis Market Size by Region (2021-2026) & ($ millions)
Table 53. Middle East & Africa Immuno-oncology Diagnosis Market Size by Technology Path (2021-2026) & ($ millions)
Table 54. Middle East & Africa Immuno-oncology Diagnosis Market Size by Application (2021-2026) & ($ millions)
Table 55. Key Market Drivers & Growth Opportunities of Immuno-oncology Diagnosis
Table 56. Key Market Challenges & Risks of Immuno-oncology Diagnosis
Table 57. Key Industry Trends of Immuno-oncology Diagnosis
Table 58. Global Immuno-oncology Diagnosis Market Size Forecast by Region (2027-2032) & ($ millions)
Table 59. Global Immuno-oncology Diagnosis Market Size Market Share Forecast by Region (2027-2032)
Table 60. Global Immuno-oncology Diagnosis Market Size Forecast by Technology Path (2027-2032) & ($ millions)
Table 61. Global Immuno-oncology Diagnosis Market Size Forecast by Application (2027-2032) & ($ millions)
Table 62. Guardant Health (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 63. Guardant Health (USA) Immuno-oncology Diagnosis Product Offered
Table 64. Guardant Health (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Guardant Health (USA) Main Business
Table 66. Guardant Health (USA) Latest Developments
Table 67. Foundation Medicine (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 68. Foundation Medicine (USA) Immuno-oncology Diagnosis Product Offered
Table 69. Foundation Medicine (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Foundation Medicine (USA) Main Business
Table 71. Foundation Medicine (USA) Latest Developments
Table 72. Illumina (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 73. Illumina (USA) Immuno-oncology Diagnosis Product Offered
Table 74. Illumina (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Illumina (USA) Main Business
Table 76. Illumina (USA) Latest Developments
Table 77. Thermo Fisher Scientific (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 78. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Product Offered
Table 79. Thermo Fisher Scientific (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Thermo Fisher Scientific (USA) Main Business
Table 81. Thermo Fisher Scientific (USA) Latest Developments
Table 82. LabCorp (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 83. LabCorp (USA) Immuno-oncology Diagnosis Product Offered
Table 84. LabCorp (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. LabCorp (USA) Main Business
Table 86. LabCorp (USA) Latest Developments
Table 87. NeoGenomics (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 88. NeoGenomics (USA) Immuno-oncology Diagnosis Product Offered
Table 89. NeoGenomics (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. NeoGenomics (USA) Main Business
Table 91. NeoGenomics (USA) Latest Developments
Table 92. Myriad Genetics (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 93. Myriad Genetics (USA) Immuno-oncology Diagnosis Product Offered
Table 94. Myriad Genetics (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Myriad Genetics (USA) Main Business
Table 96. Myriad Genetics (USA) Latest Developments
Table 97. Caris Life Sciences (USA) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 98. Caris Life Sciences (USA) Immuno-oncology Diagnosis Product Offered
Table 99. Caris Life Sciences (USA) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Caris Life Sciences (USA) Main Business
Table 101. Caris Life Sciences (USA) Latest Developments
Table 102. Roche (Switzerland) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 103. Roche (Switzerland) Immuno-oncology Diagnosis Product Offered
Table 104. Roche (Switzerland) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Roche (Switzerland) Main Business
Table 106. Roche (Switzerland) Latest Developments
Table 107. BioM?rieux (France) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 108. BioM?rieux (France) Immuno-oncology Diagnosis Product Offered
Table 109. BioM?rieux (France) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. BioM?rieux (France) Main Business
Table 111. BioM?rieux (France) Latest Developments
Table 112. QIAGEN (Netherlands) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 113. QIAGEN (Netherlands) Immuno-oncology Diagnosis Product Offered
Table 114. QIAGEN (Netherlands) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. QIAGEN (Netherlands) Main Business
Table 116. QIAGEN (Netherlands) Latest Developments
Table 117. Burning Rock Biotech (China) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 118. Burning Rock Biotech (China) Immuno-oncology Diagnosis Product Offered
Table 119. Burning Rock Biotech (China) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. Burning Rock Biotech (China) Main Business
Table 121. Burning Rock Biotech (China) Latest Developments
Table 122. Novogene (China) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 123. Novogene (China) Immuno-oncology Diagnosis Product Offered
Table 124. Novogene (China) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Novogene (China) Main Business
Table 126. Novogene (China) Latest Developments
Table 127. BGI Genomics (China) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 128. BGI Genomics (China) Immuno-oncology Diagnosis Product Offered
Table 129. BGI Genomics (China) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. BGI Genomics (China) Main Business
Table 131. BGI Genomics (China) Latest Developments
Table 132. Sysmex (Japan) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 133. Sysmex (Japan) Immuno-oncology Diagnosis Product Offered
Table 134. Sysmex (Japan) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Sysmex (Japan) Main Business
Table 136. Sysmex (Japan) Latest Developments
Table 137. Fujirebio (Japan) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 138. Fujirebio (Japan) Immuno-oncology Diagnosis Product Offered
Table 139. Fujirebio (Japan) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Fujirebio (Japan) Main Business
Table 141. Fujirebio (Japan) Latest Developments
Table 142. IMBDx (South Korea) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 143. IMBDx (South Korea) Immuno-oncology Diagnosis Product Offered
Table 144. IMBDx (South Korea) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 145. IMBDx (South Korea) Main Business
Table 146. IMBDx (South Korea) Latest Developments
Table 147. Seegene (South Korea) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 148. Seegene (South Korea) Immuno-oncology Diagnosis Product Offered
Table 149. Seegene (South Korea) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 150. Seegene (South Korea) Main Business
Table 151. Seegene (South Korea) Latest Developments
Table 152. GeneMatrix (South Korea) Details, Company Type, Immuno-oncology Diagnosis Area Served and Its Competitors
Table 153. GeneMatrix (South Korea) Immuno-oncology Diagnosis Product Offered
Table 154. GeneMatrix (South Korea) Immuno-oncology Diagnosis Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 155. GeneMatrix (South Korea) Main Business
Table 156. GeneMatrix (South Korea) Latest Developments
LIST OF FIGURES
Figure 1. Immuno-oncology Diagnosis Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immuno-oncology Diagnosis Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Immuno-oncology Diagnosis Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Immuno-oncology Diagnosis Sales Market Share by Country/Region (2025)
Figure 8. Immuno-oncology Diagnosis Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Immuno-oncology Diagnosis Market Size Market Share by Technology Path in 2025
Figure 10. Global Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers in 2025
Figure 11. Global Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios in 2025
Figure 12. Immuno-oncology Diagnosis in Research
Figure 13. Global Immuno-oncology Diagnosis Market: Research (2021-2026) & ($ millions)
Figure 14. Immuno-oncology Diagnosis in Diagnostics
Figure 15. Global Immuno-oncology Diagnosis Market: Diagnostics (2021-2026) & ($ millions)
Figure 16. Global Immuno-oncology Diagnosis Market Size Market Share by Application in 2025
Figure 17. Global Immuno-oncology Diagnosis Revenue Market Share by Player in 2025
Figure 18. Global Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Figure 19. Americas Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 20. APAC Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 21. Europe Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 23. Americas Immuno-oncology Diagnosis Value Market Share by Country in 2025
Figure 24. United States Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Immuno-oncology Diagnosis Market Size Market Share by Region in 2025
Figure 29. APAC Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Figure 30. APAC Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Figure 31. China Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 35. India Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Immuno-oncology Diagnosis Market Size Market Share by Country in 2025
Figure 38. Europe Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Figure 39. Europe Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Figure 40. Germany Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 41. France Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Figure 47. Middle East & Africa Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 54. APAC Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 55. Europe Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 57. United States Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 58. Canada Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 59. Mexico Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 60. Brazil Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 61. China Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 62. Japan Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 63. Korea Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 65. India Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 66. Australia Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 67. Germany Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 68. France Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 69. UK Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 70. Italy Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 71. Russia Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 72. Egypt Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 73. South Africa Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 74. Israel Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 75. Turkey Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 76. Global Immuno-oncology Diagnosis Market Size Market Share Forecast by Technology Path (2027-2032)
Figure 77. Global Immuno-oncology Diagnosis Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 1. Immuno-oncology Diagnosis Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immuno-oncology Diagnosis Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Immuno-oncology Diagnosis Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Immuno-oncology Diagnosis Sales Market Share by Country/Region (2025)
Figure 8. Immuno-oncology Diagnosis Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Immuno-oncology Diagnosis Market Size Market Share by Technology Path in 2025
Figure 10. Global Immuno-oncology Diagnosis Market Size Market Share by Detection Biomarkers in 2025
Figure 11. Global Immuno-oncology Diagnosis Market Size Market Share by Use Scenarios in 2025
Figure 12. Immuno-oncology Diagnosis in Research
Figure 13. Global Immuno-oncology Diagnosis Market: Research (2021-2026) & ($ millions)
Figure 14. Immuno-oncology Diagnosis in Diagnostics
Figure 15. Global Immuno-oncology Diagnosis Market: Diagnostics (2021-2026) & ($ millions)
Figure 16. Global Immuno-oncology Diagnosis Market Size Market Share by Application in 2025
Figure 17. Global Immuno-oncology Diagnosis Revenue Market Share by Player in 2025
Figure 18. Global Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Figure 19. Americas Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 20. APAC Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 21. Europe Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Immuno-oncology Diagnosis Market Size 2021-2026 ($ millions)
Figure 23. Americas Immuno-oncology Diagnosis Value Market Share by Country in 2025
Figure 24. United States Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Immuno-oncology Diagnosis Market Size Market Share by Region in 2025
Figure 29. APAC Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Figure 30. APAC Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Figure 31. China Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 35. India Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Immuno-oncology Diagnosis Market Size Market Share by Country in 2025
Figure 38. Europe Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Figure 39. Europe Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Figure 40. Germany Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 41. France Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Immuno-oncology Diagnosis Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Immuno-oncology Diagnosis Market Size Market Share by Technology Path (2021-2026)
Figure 47. Middle East & Africa Immuno-oncology Diagnosis Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Immuno-oncology Diagnosis Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 54. APAC Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 55. Europe Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 57. United States Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 58. Canada Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 59. Mexico Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 60. Brazil Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 61. China Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 62. Japan Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 63. Korea Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 65. India Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 66. Australia Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 67. Germany Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 68. France Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 69. UK Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 70. Italy Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 71. Russia Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 72. Egypt Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 73. South Africa Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 74. Israel Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 75. Turkey Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
Figure 76. Global Immuno-oncology Diagnosis Market Size Market Share Forecast by Technology Path (2027-2032)
Figure 77. Global Immuno-oncology Diagnosis Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Immuno-oncology Diagnosis Market Size 2027-2032 ($ millions)
